Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 24.68M shares rose 1.4% year over year, in line with the +1.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +11.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.4% toward the trailing-twelve-month pace of +1.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
24.68M+1.0% QoQ
Last fiscal yearDec 2025
24.44M+0.3% YoY
LTMMar 2026
24.5M+1.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.4%——
1 year+0.3%——
3-year CAGR+11.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
24.44M USD
Year-over-year change
+0.3%
4-year CAGR
+8.6%

Weighted Avg Shares vs competitors

How ARTV compares with its peers on the latest reported figures

  • ARTV's LTM Mar 2026 weighted avg shares of 24.5M shares is the 7th highest of the 9 companies compared; the peer median is 61M shares.
  • Its year-over-year change of +1.8% is the 6th highest of 9, against a peer median of +8.5%.
  • Over three fiscal years its annual growth of +11.6% compares with a peer median of +15.9%.
ARTV Competitors Peer median
Weighted Avg Shares for ARTV and competitors
Company Period LTM YoY 3-year CAGR
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 202666.33M +37.1%+16.8%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding ARTV) 61M+8.5%+15.9%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M4.93M33.49M251K0
Cost of Revenue00002.6M
Gross Profit2M4.93M33.49M251K(2.6M)
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development42.41M43.98M50.25M50.33M69.54M
Selling, General & Admin12.86M20.78M13.91M17.21M20.27M
Operating Expenses55.27M64.76M64.16M67.53M88.01M
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
EBITDA(71.58M)(57.18M)(25.36M)(56.06M)(81.27M)
EBITDA Margin-3575.3%-1159.5%-75.7%-22335.5%—
Operating Income(53.27M)(59.83M)(30.67M)(67.28M)(90.61M)
Operating Margin-2660.9%-1213.3%-91.6%-26805.6%—
Interest Income01.29M2.54M5.35M5.96M
Interest Expense00000
Other Income / Expenses(18.55M)1.49M3.05M8.79M6.75M
Income Before Tax(71.83M)(58.34M)(27.62M)(58.49M)(83.87M)
Pre-Tax Margin-3587.7%-1183.0%-82.5%-23304.0%—
Income Tax Expense053K72K00
Net Income(71.83M)(58.39M)(27.7M)(58.49M)(83.87M)
Net Margin-3587.7%-1184.1%-82.7%-23304.0%—
EPS (Basic)(4.08)(3.32)(1.19)(5.20)(3.43)
EPS (Diluted)(4.08)(3.32)(1.19)(5.20)(3.43)
Weighted Avg Shares17.58M17.58M23.28M24.36M24.44M
Weighted Avg Shares (Diluted)17.58M17.58M23.28M24.36M24.44M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.